A new form of cell death called triaptosis is starting to attract attention as a potential way to treat hard‑to‑kill cancers. The idea behind it is quite simple: instead of trying to push tumor cells into the classic death routes that many of them have already learned to escape, triaptosis hits them somewhere they are […]
Insilico Medicine has nominated ISM3830, a potentially best-in-class oral CBLB inhibitor discovered through its proprietary Chemistry42 AI platform, as a preclinical candidate for advanced cancer immunotherapy. This novel molecule targets Casitas B-lineage lymphoma-b (CBLB), an intracellular E3 ubiquitin ligase that acts as a master negative regulator of T-cell and natural killer (NK) cell activation, distinct […]
ITC-6146RO is an experimental cancer drug belonging to the class of antibody–drug conjugates, or ADCs. It received IND Approval from Korean Ministry of Food and Drug Safety (Following U.S. FDA) to start a first‑in‑human Phase 1 trial in people with advanced or metastatic solid tumors who no longer respond to standard therapies. It has been […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This week we have six interesting clinical trials. I’ve had a very busy week (one of my dogs is seriously ill and I’ve been at the vet very often!) and the preclinical research I managed to read is very […]
MK-6070 (Gocatamig) is an engineered trispecific T-cell engager designed to target a protein called DLL3, which is predominantly found on certain aggressive neuroendocrine tumors, including prostate cancer. This molecule works by simultaneously binding to DLL3 on tumor cells, the CD3 receptor on T cells, and serum albumin, which extends the drug’s circulation time in the […]
We have already talked about it here, GenSci143, is a novel bispecific antibody-drug conjugate targeting B7-H3 and PSMA, and a phase 1 trial is set to begin first-in-human clinical trials soon (est. date December 20) in participants with advanced solid tumors, including metastatic castration-resistant prostate cancer. Recent regulatory approvals were granted by the U.S. FDA […]
A clinical trial at Zhongda Hospital in China is testing a combination of fasudil hydrochloride, a Rho-associated kinase (ROCK) inhibitor, with PD-1 immune checkpoint blockade in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). This Phase II open-label trial enrolls patients aged 18 to 85 years who have progressed after at least one docetaxel-containing chemotherapy […]
A phase 1/2 clinical trial investigating valemetostat (DS-3201b), a dual EZH1/2 inhibitor, combined with darolutamide in metastatic castration-resistant prostate cancer (mCRPC) is going to start to recruit participants. This study aims to evaluate the safety, tolerability, and preliminary efficacy of the combination in men whose disease has progressed despite prior androgen receptor pathway inhibitors (ARPIs). […]
A pivotal clinical trial is underway to evaluate the safety and efficacy of combining Lutetium (177Lu) DGUL radioligand therapy with pembrolizumab (Keytruda) for treating metastatic castration-resistant prostate cancer in patients who have progressed after androgen receptor-targeted therapies but have not yet received chemotherapy. The study enrolls men with prostate-specific membrane antigen (PSMA)-positive tumors, with disease […]
GTB-5550, a novel tri-specific natural killer (NK) cell engager drug designed to target the B7-H3 antigen has shown notable promise in advancing cancer immunotherapy for solid tumors, particularly prostate cancer and head and neck squamous cell carcinoma (HNSCC). This drug functions by simultaneously binding to CD16 on NK cells, engaging B7-H3 expressed on tumor cells, […]